Key result
Prophylactic adeno-mediated overexpression of Hsp22 in the swine heart reduced infarct size by 40% and improved regional wall thickening compared to LacZ controls.
Why the study?
Does prophylactic overexpression of Hsp22 reduce ischemic damage in a swine model of myocardial ischemia?
Does prophylactic overexpression of Hsp22 reduce ischemic damage in a swine model of myocardial ischemia?
Short-term prophylactic overexpression of Hsp22 provides NO-dependent cardioprotection, offering a potential alternative to ischemic preconditioning for preemptive treatment of myocardial ischemia.
Answers are grounded in this paper and cite their sources.
Should not yet change clinical practice; leaves open Hsp22 overexpression as a hypothesis-generating target for ischemic preconditioning alternatives.
The second window of ischemic preconditioning (SWOP) provides maximal protection against ischemia through regulation of the inducible nitric oxide synthase (iNOS), yet its application is limited by the inconvenience of the preliminary ischemic stimulus required for prophylaxis. Overexpression of H11 kinase/Hsp22 (Hsp22) in a transgenic mouse model provides cardioprotection against ischemia that is equivalent to that conferred by SWOP. We hypothesized that short-term, prophylactic overexpression of Hsp22 would offer an alternative to SWOP in reducing ischemic damage through a nitric oxide (NO)-dependent mechanism. Adeno-mediated overexpression of Hsp22 was achieved in the area at risk of the left circumflex (Cx) coronary artery in chronically instrumented swine and compared with LacZ controls (n = 5/group). Hsp22-injected myocardium showed an average fourfold increase in Hsp22 protein expression compared with controls and a doubling in iNOS expression (both P < 0.05). Four days after ischemia-reperfusion, regional wall thickening was reduced by 58 ± 2% in the Hsp22 group vs. 82 ± 7% in the LacZ group, and Hsp22 reduced infarct size by 40% (both P < 0.05 vs. LacZ). Treatment with the NOS inhibitor N(G)-nitro-L-arginine (L-NNA) before ischemia suppressed the protection induced by Hsp22. In isolated cardiomyocytes, Hsp22 increased iNOS expression through the transcription factors NF-κB and STAT, the same effectors activated by SWOP, and reduced by 60% H(2)O(2)-mediated apoptosis, which was also abolished by NOS inhibitors. Therefore, short-term, prophylactic conditioning by Hsp22 provides NO-dependent cardioprotection that reproduces the signaling of SWOP, placing Hsp22 as a potential alternative for preemptive treatment of myocardial ischemia.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2011) studied Myocardial ischemia-reperfusion injury. Adeno-mediated overexpression of Hsp22 vs. LacZ control was evaluated on Reduction in regional wall thickening 4 days after ischemia-reperfusion (p=<0.05). Prophylactic adeno-mediated overexpression of Hsp22 in the swine heart reduced infarct size by 40% and improved regional wall thickening compared to LacZ controls.
Synapse has enriched 10 related papers. Consider them for comparative context: